Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. — Investor Relations & Filings

Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Open in API
Filings indexed 783 across all filing types
Latest filing 2021-02-02 Regulatory Filings
Country US United States of America
Listing US MBRX

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 2, 2021, by Moleculin Biotech, Inc. It primarily announces a press release about a preclinical study result. The document length is 3788 characters, which is relatively short and mainly serves as a current report to disclose material information promptly. It includes a press release as an exhibit but does not contain detailed financial statements or comprehensive financial analysis. The content is a regulatory announcement of a material event rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2021-02-02 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 1, 2021. It announces a press release about a clinical trial agreement but does not contain financial statements or detailed financial data. The document length is 3904 characters, which is relatively short and primarily serves as a disclosure of a corporate event rather than a full financial report. The presence of a press release as an exhibit and the nature of the content indicate this is a regulatory announcement rather than a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2021-02-01 English
FORM 8-K
Share Issue/Capital Change Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated January 29, 2021, by Moleculin Biotech, Inc. It announces a corporate action: a 1-for-6 reverse stock split of the company's common stock, approved by stockholders and executed by the board of directors. The document includes details about the reverse stock split, its effective date, and the impact on shares outstanding and stock options. It also references exhibits including the certificate of amendment and a press release. The content is focused on a capital structure change (reverse stock split), which is a capital change event. The document is not a full financial report, earnings release, or management discussion, but a regulatory filing announcing a capital change. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length (7164 characters) supports it being a full filing rather than a brief announcement or certification.
2021-01-29 English
MOLECULIN BIOTECH, INC.
Major Shareholding Notification
2021-01-20 English
FORM 8-K
Investor Presentation Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by Moleculin Biotech, Inc. dated January 11, 2021. It specifically mentions that the attached Exhibit 99.1 is an "Investor Presentation dated January 2021." The text clarifies that the presentation is being furnished and is not considered "filed" for regulatory purposes. The document itself is short (3581 characters) and primarily serves to announce the filing and availability of the investor presentation. There is no substantive financial data or detailed report content within this text, only a reference to the investor presentation as an exhibit. According to the classification rules, this is an announcement of an investor presentation, and the exhibit itself is the presentation. Therefore, the correct classification is Investor Presentation (IP).
2021-01-11 English
SABBY 13G-A MBRX 1.04.21
Major Shareholding Notification
2021-01-04 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.